paul collins

Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage

Great article very informative some other facts



Analyst has $6 Target stock is $1.25

Generex Biotechnology "market outperform"
01/16/08 - Rodman & Renshaw
NEW YORK, January 16 (newratings.com) - Analysts at Rodman & Renshaw reiterate their "market outperform" rating on Generex Biotechnology Corp (GNBT). The target price is set to $6.

In a research note published this morning, the analysts mention that the execution of the company’s low-risk Oral-lyn pre-commercialization activities and the preparations for the late-stage Phase III clinical trial are on track. Generex Biotechnology is a leading player in the alternative drug delivery market, the analysts add.



www.newratings.com/en/...


Flaherty Special Situation #2
Volume 1 Issue 2
April 2008
~~~~~~~~~~~~~~~~~~~~~~...

in this issue
Bob Flaherty Rides Again! Generex Biotechnology Corporation (NASDAQ:GNBT) is his next winner.

What exciting special situation have we found for you this issue? Take a look at Generex Biotechnology, whose stock was recently $1.04 versus a 12 month high of $2.14 and an all time high of over $22. Rodman and Renshaw forecasts a 12 month stock price of $6 and after that we think further gains are possible. GNBT is successful pioneering to introduce global needle-free delivery of insulin where many famous giants and lots of others have failed. You may even know of a person who is a diabetic who could improve the quality of their life if instead of using needles all the time they could switch to Generex Biotechnology's oral insulin spray after it is approved in the U.S. as it already is in Eucador and India.Think of how many of the 194 million diabetics in the world who would benefit if they coulld change the way that they take in insulin.

archive.constantcontac...